Artiva Biotherapeutics, Inc. Common Stock (ARTV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Artiva Biotherapeutics, Inc. Common Stock (ARTV) has a cash flow conversion efficiency ratio of -0.149x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.20 Million) by net assets ($129.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Artiva Biotherapeutics, Inc. Common Stoc to measure how much of total assets are equity-financed.
Artiva Biotherapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Artiva Biotherapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Artiva Biotherapeutics, Inc. Common Stoc to evaluate the quality of earnings relative to operating cash generation.
Artiva Biotherapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Artiva Biotherapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inscobee
KO:006490
|
0.020x |
|
Netbay Public Company Limited
BK:NETBAY
|
0.159x |
|
Autocount Dotcom Berhad
KLSE:0276
|
0.035x |
|
Orthex Oyj
HE:ORTHEX
|
0.158x |
|
SHEPHERD NEAME P. CONS.
F:43Y
|
N/A |
|
Highland Copper Company Inc.
V:HI
|
-0.087x |
|
Nanexa AB
ST:NANEXA
|
-0.040x |
|
FM Global Logistics Holdings Bhd
KLSE:7210
|
0.028x |
Annual Cash Flow Conversion Efficiency for Artiva Biotherapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual cash flow conversion efficiency of Artiva Biotherapeutics, Inc. Common Stock from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Artiva Biotherapeutics, Inc. Common Stoc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $186.64 Million | $-55.03 Million | -0.295x | -200.72% |
| 2023-12-31 | $-162.01 Million | $-47.43 Million | 0.293x | -18.97% |
| 2022-12-31 | $-140.70 Million | $-50.83 Million | 0.361x | +109.76% |
| 2021-12-31 | $-88.86 Million | $-15.30 Million | 0.172x | -72.57% |
| 2020-12-31 | $-21.57 Million | $-13.54 Million | 0.628x | -- |
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus n… Read more